JP2011524858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524858A5 JP2011524858A5 JP2011509761A JP2011509761A JP2011524858A5 JP 2011524858 A5 JP2011524858 A5 JP 2011524858A5 JP 2011509761 A JP2011509761 A JP 2011509761A JP 2011509761 A JP2011509761 A JP 2011509761A JP 2011524858 A5 JP2011524858 A5 JP 2011524858A5
- Authority
- JP
- Japan
- Prior art keywords
- psgl
- binding
- human
- selectin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010054395 P-selectin ligand protein Proteins 0.000 claims 32
- 239000012634 fragment Substances 0.000 claims 29
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 21
- 210000000265 leukocyte Anatomy 0.000 claims 14
- 210000004698 lymphocyte Anatomy 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 210000002889 endothelial cell Anatomy 0.000 claims 12
- 108010092694 L-Selectin Proteins 0.000 claims 9
- 102000016551 L-selectin Human genes 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 238000012360 testing method Methods 0.000 claims 7
- 102100021942 C-C motif chemokine 28 Human genes 0.000 claims 6
- 102000019034 Chemokines Human genes 0.000 claims 6
- 108010012236 Chemokines Proteins 0.000 claims 6
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000009977 dual effect Effects 0.000 claims 6
- 102100021936 C-C motif chemokine 27 Human genes 0.000 claims 4
- 108010082161 Chemokine CCL19 Proteins 0.000 claims 4
- 102000003805 Chemokine CCL19 Human genes 0.000 claims 4
- 102000009109 Fc receptors Human genes 0.000 claims 4
- 108010087819 Fc receptors Proteins 0.000 claims 4
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108010083702 Chemokine CCL21 Proteins 0.000 claims 3
- 102000006435 Chemokine CCL21 Human genes 0.000 claims 3
- 108010083675 Chemokine CCL27 Proteins 0.000 claims 3
- 102000006387 Chemokine CCL27 Human genes 0.000 claims 3
- 108010035766 P-Selectin Proteins 0.000 claims 3
- 102100023472 P-selectin Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000024203 complement activation Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000005012 migration Effects 0.000 claims 3
- 238000013508 migration Methods 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010061430 Arthritis allergic Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 102000003800 Selectins Human genes 0.000 claims 1
- 108090000184 Selectins Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 230000034196 cell chemotaxis Effects 0.000 claims 1
- 230000003399 chemotactic effect Effects 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12779108P | 2008-05-15 | 2008-05-15 | |
| US61/127,791 | 2008-05-15 | ||
| PCT/US2009/044188 WO2009140623A2 (en) | 2008-05-15 | 2009-05-15 | Anti-psgl-1 antibodies and methods of identification and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011524858A JP2011524858A (ja) | 2011-09-08 |
| JP2011524858A5 true JP2011524858A5 (enExample) | 2012-05-10 |
Family
ID=41316376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509761A Pending JP2011524858A (ja) | 2008-05-15 | 2009-05-15 | 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7833530B2 (enExample) |
| EP (2) | EP3388527A1 (enExample) |
| JP (1) | JP2011524858A (enExample) |
| AU (1) | AU2009246166B2 (enExample) |
| CA (1) | CA2724415C (enExample) |
| WO (1) | WO2009140623A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377440B2 (en) | 2006-12-01 | 2013-02-19 | Selexys Pharmaceuticals Corporation | Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases |
| US8945565B2 (en) | 2006-12-01 | 2015-02-03 | Selexys Pharmaceuticals Corporation | Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies |
| EP3222635A1 (en) * | 2010-12-21 | 2017-09-27 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of their use and identification |
| CN116063522A (zh) * | 2011-06-13 | 2023-05-05 | 美国全心医药生技股份有限公司 | 抗psgl-1抗体及其用途 |
| JP6236255B2 (ja) * | 2012-08-31 | 2017-11-22 | 旭化成メディカル株式会社 | 基材及びデバイス |
| JP7244422B2 (ja) | 2017-01-11 | 2023-03-22 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｓｇｌ－１アンタゴニスト及びその使用 |
| SG11201907848YA (en) | 2017-03-14 | 2019-09-27 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
| KR20200003160A (ko) * | 2017-05-03 | 2020-01-08 | 바이오마린 파머수티컬 인크. | 조혈모세포의 형질도입을 위한 개선된 렌티바이러스 |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| US20210189342A1 (en) * | 2018-06-29 | 2021-06-24 | Verseau Therapeutics, Inc. | Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof |
| US12091462B2 (en) | 2018-07-11 | 2024-09-17 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic pH |
| CN118994395A (zh) | 2018-07-20 | 2024-11-22 | 皮埃尔法布雷医药公司 | Vista受体 |
| TW202110891A (zh) * | 2019-06-04 | 2021-03-16 | 美商維西歐製藥公司 | 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途 |
| KR102242285B1 (ko) * | 2019-10-02 | 2021-04-20 | 코아스템(주) | 중간엽줄기세포의 전신홍반루푸스 치료효과 예측용 바이오마커 조성물 |
| CN113322223B (zh) * | 2021-06-03 | 2023-09-12 | 重庆市畜牧科学院 | 富硒酵母基因工程菌及其表面展示系统及其构建方法 |
| CN113667015B (zh) * | 2021-08-20 | 2022-10-11 | 北京康特泊瑞生物医药科技股份公司 | 靶向psgl-1蛋白的抗体及其用途 |
| CN120265323A (zh) * | 2022-09-13 | 2025-07-04 | 泰克斯制药公司 | 抗体、组合物和治疗方法 |
| WO2025191538A1 (en) * | 2024-03-14 | 2025-09-18 | Tetherex Pharmaceuticals Corporation | Pharmaceutical compositions and methods of treatment |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7016A (en) * | 1850-01-15 | Mill for grinding | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US6277975B1 (en) * | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US7223845B2 (en) | 1998-06-16 | 2007-05-29 | The Board Of Regents Of The University Of Oklahoma | Synthetic glycosulfopeptides and methods of synthesis thereof |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US20020031508A1 (en) * | 2000-05-19 | 2002-03-14 | Wagner Denisa D. | Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity |
| US20040002450A1 (en) * | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040001839A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US7744888B2 (en) * | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| US20040072796A1 (en) * | 2002-04-18 | 2004-04-15 | Embury Stephen H. | Method and composition for preventing pain in sickle cell patients |
| WO2005007809A2 (en) * | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| US20050069955A1 (en) * | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| US20070160601A1 (en) * | 2005-12-09 | 2007-07-12 | Angela Widom | Neutralizing antibodies against primate psgl-1 and uses therefor |
| WO2007067983A2 (en) * | 2005-12-09 | 2007-06-14 | Wyeth | Sulfotyrosine specific antibodies and uses therefor |
| EP2029621A2 (en) * | 2006-06-07 | 2009-03-04 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
-
2009
- 2009-05-15 AU AU2009246166A patent/AU2009246166B2/en active Active
- 2009-05-15 JP JP2011509761A patent/JP2011524858A/ja active Pending
- 2009-05-15 CA CA2724415A patent/CA2724415C/en active Active
- 2009-05-15 WO PCT/US2009/044188 patent/WO2009140623A2/en not_active Ceased
- 2009-05-15 US US12/467,060 patent/US7833530B2/en active Active
- 2009-05-15 EP EP18154983.3A patent/EP3388527A1/en active Pending
- 2009-05-15 EP EP09747704A patent/EP2291536A4/en not_active Ceased
-
2010
- 2010-11-15 US US12/946,372 patent/US20110081666A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524858A5 (enExample) | ||
| JP2011520898A5 (enExample) | ||
| CA2850549C (en) | Antibodies against tl1a and uses thereof | |
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2015535820A5 (enExample) | ||
| JP2012501669A5 (enExample) | ||
| JP5150488B2 (ja) | Ｆｃ領域含有タンパク質を精製する方法 | |
| JP2011256213A5 (enExample) | ||
| JP2023021414A (ja) | Ｃｄ１９に特異的な抗体およびキメラ抗原受容体 | |
| JP5745854B2 (ja) | Ｔｌ１ａに対するヒト化抗体 | |
| JP2018520667A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| CN102971342B (zh) | 亲和力降低的新抗体和制备所述抗体的方法 | |
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2019162105A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| JP2014527802A5 (enExample) | ||
| JP2014111644A5 (enExample) | ||
| JP2010501164A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2016505634A5 (enExample) | ||
| JP2014518883A5 (enExample) |